BioAge Labs 3Q 2026: Revenue $298K, EPS ($0.73) — 10-Q Summary
BioAge Labs (BIOA) reported 3Q 2026 revenue of $298K, down 85% YoY, and a net loss of $33.5M, up 66% YoY. The decline was due to a $1.7M adjustment in Novartis collaboration revenue. R&D costs rose 63% to $30.2M, driven by BGE-102 trial and manufacturing expenses. The company completed QUELL-CV enrollment and expects topline data in 4Q 2026.
How this was made

The 30-second read
Why it matters
The earnings miss deepens the company's cash‑burn profile, likely prompting short‑term price declines.
Market read
Primary earnings disclosure for a micro‑cap biotech; relevant for traders tracking biotech sector risk and cash‑flow dynamics.
What to watch
The $0.9M increase in Novartis funding cap may provide runway despite current short‑term loss.
Background
BioAge Labs is a clinical‑stage biotech focused on aging therapeutics. The 10‑Q filing provides the first public disclosure of Q3 2026 results.
Ticker impact
BioAge Labs reported Q3 2026 revenue of $298K, an 85% YoY decline, and a net loss of $33.5M, widening 66% YoY.
likely pressure as the market prices in the revenue collapse and loss expansion
Earnings miss on both top and bottom line for a micro‑cap biotech typically triggers sell‑offs, especially with increased R&D spend and no offsetting news.
Market effects
May weigh on other early‑stage biotech stocks as investors reassess cash‑burn expectations.
Limited to US biotech sector; no broader regional effect.
Minimal global impact beyond niche biotech investors.
Counterpoint
If the Novartis collaboration expands further, the cash burn could translate into future upside.
Key entities
- companyBioAge Labs, Inc.
US‑listed biotech reporting Q3 2026 results.
- partnerNovartis
Collaboration partner providing research funding.